尤瑞克林联合鼠神经生长因子治疗急性缺血性脑卒中

Clinical study of urinary kallidinogenase combined with mouse nerve growth factor in the treatment of acute ischemic stroke

目的:探讨尤瑞克林联合鼠神经生长因子治疗急性缺血性脑卒中的临床疗效。方法:选取收治的150例急性缺血性脑卒中患者,随机将其分成对照组和观察组,每组各75例患者,其中对照组患者给予尤瑞克林治疗,观察组患者给予尤瑞克林联合鼠神经生长因子治疗,治疗第28天时比较两组患者的临床疗效、NIHSS、GCS以及MMSE评分、血清VEGF、hs-CRP以及S100B含量和不良反应情况。结果:观察组患者治疗总有效率(86.7%)显著高于对照组患者(66.7%,P<0.05);观察组患者治疗后NIHSS评分显著低于对照组患者,GCS以及MMSE评分显著高于对照组患者(P<0.05);观察组患者治疗后血清VEGF含量显著高于对照组患者,血清hs-CRP和S100B含量显著低于对照组患者(P<0.05);两组患者不良反应数据比较差异无统计学意义(P>0.05)。结论:尤瑞克林联合鼠神经生长因子治疗急性缺血性脑卒中疗效显著,可以显著改善患者的临床症状,且安全性高。

Objective To investigate the efficacy and safety of urinary kallidinogenase combined with mouse nerve growth factor in the treatment of acute ischemic stroke. Methods 150 cases of acute ischemic stroke patients （hospitalized from January 2013 to January 2015） in Central Hospital of Wuhan are included in this research. The patients were randomly divided into the control group and observation group. The control group were treated with urinary kallidinogenase, and the observation group were treated with urinary kallidinogenase czmhined with mouse nerve growth factor treatment. At the 28th day of the treatment, clinical efficacy, NIHSS, GCS and MMSE score, serum vascular endothelial growth factor （VEGF）, hs-CRP and serum S100B and adverse reactions of the two groups of patients were compared. Results The total efficiency of the patients in the observation group （85.7%） was significantly higher than that of the control group （66.7%） （P 〈 0.05）. The NIHSS score of the patients in observation group was significantly lower than that of the patients in the control group, the GCS and MMSE score was significantly higher than that of the patients in the control group （P 〈 0.05）. After treatment, the content of serum VEGF of the patients in the observation group was significantly higher than that of the patients in the control group, serum hs-CRP and S100B content were significantly lower than that of the patients in the control group （P 〈 0.05）. The differences of adverse reaction between the two groups of patients were not statistically significant （P 〉 0.05）. Conclusion Urinary kallidinogenase combined with mouse nerve growth factor has significant effect in the treatment of acute ischemic stroke. It can significantly improve the patient＇s clinical symptoms safely, which is worthy of clinical application.